35 results about "Meter dose inhaler" patented technology

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

An improved stem block for an inhaler that is fired in an upright orientation, providing easier and more reliable delivery of aerosols. The disclosed stem block demonstrates atomization efficiency that is superior to the performance of a conventional metered dose inhaler. The stem block has a passage that connects to a narrower expansion chamber. The expansion chamber connects to an exit orifice that is narrower than the expansion chamber. The exit orifice further connects to a conical outlet for dispensing an aerosol. The passage, the expansion chamber, and the exit orifice are axially aligned.

The present invention relates to a device (20) for delivering a drug (30) to a user via a nasal or pulmonary route. The device can be a pressurised metered dose inhaler (200), an active dry powder inhaler (300 / 400) a soft mist inhaler (500) or a nebuliser (600). The device (20) comprises a propellant energy source (40) to deliver a drug (30), which propellant energy source (40) is or comprises an aerial gas (41) that is stored in a canister (45) separate of the drug, at a pressure of at least 2 Bar, adsorbed on an adsorbant (42) where it is released therefrom to dispense the drug (30). The device comprises a gas delivery mechanism (50) wth a metering chamber (52) which has a larger capacity than a traditional pressuised metered dose inhaler which is filler with an HFC propellant. The aerial gas (41) is released from the chamber on actuation and travels along a conduit (25) to displace a dose of a drug (30) from a dosing chamber (80) which is aerosolised and leaves the device via a second conduit (27) and exit (28) as a plume (60).

An electronic module for a metered dose inhaler comprises a housing (10) having a front wall (13) configured to face a rear side (6a) of a housing (6) of the metered dose inhaler (2), a rear wall (16) opposite the front wall (13), and a side wall (17) extending between the front wall (13) and the rear wall (16). An electronics unit (11) is mounted inside the housing (10) and comprises a capacitive proximity device (29) with a capacitive sensor antenna (30). The capacitive sensor antenna (30) is disposed against or near an inner surface of a rear wall (16) and / or a side wall (17) of the housing (10).

The present invention relates to a device (20) for delivering a medicament (30) to a user via the nasal or pulmonary route. The device may be a pressurized metered dose inhaler (200), an active dry powder inhaler (300 / 400), a soft mist inhaler (500), or a nebulizer (600). The device (20) comprises a propellant energy source (40) for delivering the medicament (30), the propellant energy source (40) being or comprising an atmospheric gas (41) stored in a canister (45) separate from the medicament, adsorbed on an adsorbate (42) at a pressure of at least 2 bar, the atmospheric gas being released from the canister to dispense the medicament (30). The device includes a gas delivery mechanism (50) having a metering chamber (52) that has a greater capacity than a conventional pressurized metered dose inhaler filled with HFC propellant. The atmospheric-like gas (41), upon actuation, is released from the chamber and travels along the conduit (25) to displace a dose of medicament (30) from the dose chamber (80) undergoing aerosolization and exit the device as a plume (60) via a second conduit (27) and an outlet (28).

The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The invention discloses a self-adaptive inspiration flow trigger type asthma quantitative inhaler which comprises an actuating shell, a gallipot storage shell is arranged in the actuating shell, a gallipot is arranged in the gallipot storage shell, and a pressing mechanism is arranged in the actuating shell and located above the gallipot storage shell. A limiting block is arranged outside the gallipot storage shell, a stud is arranged on the outer side of the actuating shell, a triggering mechanism is arranged on the stud, a stopping mechanism is arranged on the outer side of the actuating shell and located below the triggering mechanism, and a flow meter is arranged on the outer side of the actuating shell and located below the stopping mechanism. The self-adaptive inspiration flow triggering type quantitative inhaler has the beneficial effects that the self-adaptive inspiration flow triggering type quantitative inhaler can ensure that a patient can inhale medicine at the optimal time under the current inspiration condition under different inspiration conditions of the patient, the oral-laryngeal deposition rate of the medicine is reduced, and the administration efficiency is improved.

A metered dose inhaler comprising: a metering valve; a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises a formulation, the formulation comprising greater than 70% by weight of HFO-1234ze(E); and at least one active pharmaceutical ingredient suspended in the formulation; wherein the metered dose inhaler delivers at least 0.5 milligram (mg) of the at least one active pharmaceutical ingredient per actuation. A metered dose inhaler comprising: a metering valve; a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises a formulation, the formulation comprising greater than 70% by weight of HF A-152a; and at least one active pharmaceutical ingredient suspended in the formulation; wherein the metered dose inhaler delivers at least 0.5 milligram (mg) of the at least one active pharmaceutical ingredient per actuation.

A metered dose inhaler storage container comprising a packaging carton (1) having an opening (3) at an opposite end of the packaging carton (1), comprising an inlet opening at one end of the packaging carton (1) for receiving a mouthpiece (4) of a metered dose inhaler (5), and an associated outlet opening (3) at an opposite end of the packaging carton (1), the invention relates to a packaging carton (1) for engagement through the mouth of a user (6) to inhale the medicament expelled from a metered dose inhaler (5) through the packaging carton (1) forming a spacer of the metered dose inhaler (5). The metered dose inhaler (5) is supplied in the packaging carton (1) and stored within the packaging carton (1) when not in use. The packaging carton (1) forms a storage container and a spacer for metered dose inhalers (5).

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

The present disclosure discloses an aerosol actuator and a metered dose inhaler. The aerosol actuator comprises a housing and a counting unit; the housing comprises a housing body and a nozzle, the housing body being configured to communicate with the nozzle; the housing body being configured to accommodate the counting unit; the counting unit comprises a gear fixing member, a counting gear, a driving element, and an elastic member; a cavity is formed inside the gear fixing member; the counting gear is arranged in the cavity; the gear fixing member comprises a cover plate part, the cover plate part comprising a cover plate part body and a check pawl; a surface of the counting gear that is close to the cover plate part body is provided with a limiting recess; the check pawl is arranged on the cover plate part body, and the check pawl is configured to coordinate with a meshing tooth of the counting gear so as to limit a rotation direction of the counting gear; the check pawl is provided with a limiting protrusion, the limiting protrusion being configured to coordinate with the limiting recess so as to limit a rotation direction of the counting gear. The aerosol actuator enables the counting to be more accurate.

An inspection unit for cans (11), in particular for metal cans used in metered dose inhalers or for the manufacture of batteries, comprising a visual inspection unit (9) comprising camera units (20), a conveying unit (8), wherein images of the individual cans are captureable by different camera units from different viewing angles, wherein the camera units each capture a plurality of cans simultaneously in an image comprising a plurality of image portions (24) including images of an outer surface portion of each of said plurality of cans from a different viewing angle, the image portions including images of outer side surface portions (22) and the outer bottom surface portion (19) of each can, the sum of the images of the outer side surface portions covering the entire outer side surface of the can; and a processing unit to process the captured images portions and to determine an inspection result.

Various embodiments of a metered dose inhaler are disclosed. The inhaler includes a metering valve, a canister, and an actuator having an actuator nozzle. The canister includes a formulation having a propellant including HFO-1234ze(E), at least 1% of ethanol by weight, and one or more cannabinoids, wherein the one or more cannabinoids is dissolved in the formulation to form a solution. In one or more embodiments, the cannabinoid includes tetrahydrocannabinol (THC) and / or cannabidiol (CBD).

An electronic module for a metered dose inhaler comprises a casing (10) having an external surface (17) provided with a pressure detection point (16), an electronic unit (11) and a pressure sensor (13) enclosed in the casing (10). The pressure sensor (13) is operatively connected to the electronic unit (11) and to the pressure detection point (16). The casing (10) comprises two hooks (19) configured to engage an edge (9) of a housing (6) of a metered dose inhaler (2) accommodating a canister (5) containing a drug formulation to be dispensed. The pressure detection point (16) is located between the two hooks (19). The electronic module is attachable to the metered dose inhaler.

A pressurised metered dose inhaler 200, an active dry powder inhaler, a soft mist inhaler or a nebuliser comprising a device 20 comprising canister walls 23 and an end face 24. The inhaler comprises a

The present invention relates to a metered dose inhaler device comprising a stable inhalable composition of ipratropium bromide, contained in a canister fitted with a metering valve, an actuator and a dose indicator. The present invention also relates to a process for preparing such a pharmaceutical composition and its use in the treatment of respiratory disorders such as for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in a subject in need thereof (e.g., a human).

A breath-actuated metered dose inhaler includes a housing, a canister, and a trigger mechanism. A trigger mechanism is actuated by suction of air, the trigger mechanism including a diaphragm. The central rigid disc of the diaphragm is provided with interlocking means to securely secure and bond the peripheral flexible polymer ring to the central rigid disc. A mechanical interlock between the central rigid disc and the peripheral flexible polymer ring on the diaphragm prevents peeling of the peripheral flexible polymer ring from the central rigid disc while maintaining a vacuum prior to suction.

Various embodiments of a metered dose inhaler are disclosed. The inhaler includes a metering valve, a canister, and an actuator having an actuator nozzle. The canister contains a formulation having a propellant including HFA-152a, at least 1% by weight ethanol, and one or more cannabinoids, the one or more cannabinoids dissolved in the formulation to form a solution. In one or more embodiments, the cannabinoids include tetrahydrocannabinol (THC) and / or cannabidiol (CBD).

An electronic module for a metered dose inhaler comprises a casing (10) having a front wall (13) configured to face a back side (6a) of a housing (6) of a metered dose inhaler (2), a back wall (16) opposite the front wall (13) and a side wall (17) extending between the front wall (13) and the back wall (16). An electronic unit (11) is installed inside the casing (10) and comprises a capacitive proximity device (29) having a capacitive sensor antenna (30). The capacitive sensor antenna (30) is placed against or close to an inner surface of the back wall (16) and / or the side wall (17) of the casing (10).

Various embodiments of a metered dose inhaler are disclosed. The inhaler includes a metering valve, a canister, and an actuator having an actuator nozzle. The canister includes a formulation having a propellant including HFA-152a, at least 1% of ethanol by weight, and one or more cannabinoids, wherein the one or more cannabinoids is dissolved in the formulation to form a solution. In one or more embodiments, the cannabinoid includes tetrahydrocannabinol (THC) and / or cannabidiol (CBD).

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze (E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The present invention generally relates to an aerosol formulation comprising formoterol and beclomethasone dipropionate, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the teratment of respiratory diseases.

The present invention relates to a lidocaine hydrochloride nasal composition associated with pharmacologically acceptable components in a portion of 1 ml to 1.8 ml of a highly concentrated, stable, clear transparent solution, with concentrations of lidocaine hydrochloride varying from around 1000 mcg / 0.05 ml to around 1500 mcg / 0.05 ml per drop, with a pH varying between around 6.0 and around 7.0 and a viscosity varying from around 1 to 100 cps, said combination being suitable for systemic intranasal release, administered in drops or assisted devices - metered dose inhalers, mDIs, around (0.05 ml to 0.20 ml) or (0.0166 ml to 0.05 ml = 1 to 3) being the necessary minimum for a therapeutic effect. Use thereof is recommended for mammals heavier than 200 g.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.

An apparatus and method are provided for administering an inhaled drug to a person while simultaneously administering oxygen from a medical oxygen mask. The inhaled drug is from a pressurized metered dose inhaler (MDI), employing an extender tube about 3-10 cm long that fits into or over the mouthpiece of the inhaler. The MDI with extender tube is inserted into the mask and positioned so that the plume of drug travels through the extender when the MDI is actuated and is directed to just inside the mouth of the person. In an embodiment, an exhalation filter is provided to prevent contamination from infectious agents in the exhaled air from the person.

An electronic module for a metered dose inhaler, the electronic module comprising: a housing (10) having an outer surface (17) provided with a pressure detection point (16); an electronic unit (11) and a pressure sensor (13) enclosed in the housing (10). The pressure sensor (13) is operatively connected to the electronic unit (11) and to the pressure detection point (16). The housing (10) comprises two hooks (19) configured to engage an edge (9) of a housing (6) of the metered dose inhaler (2), the housing containing a canister (5) containing the pharmaceutical preparation to be dispensed. A pressure detection point (16) is located between the two hooks (19). The electronics module is attachable to the metered dose inhaler.

To provide a formulation particularly useful for use in a pressurised metered dose inhaler for the treatment of respiratory diseases.SOLUTION: The present invention relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated can.SELECTED DRAWING: None

The present invention relates to a metered dose inhaler device comprising a stable inhalable composition of ipratropium bromide, contained in a canister fitted with a metering valve, an actuator and a dose indicator. The present invention also relates to a process for preparing such a pharmaceutical composition and its use in the treatment of respiratory disorders such as for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in a subject in need thereof (e.g., a human).

The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.